Progressive multiple sclerosis: Six trials to watch

Area of Science:

• Neuroimmunology
• Clinical Therapeutics
• Translational Medicine

Background:

• Progressive multiple sclerosis (PMS) is characterized by CNS inflammation, driving disease progression independently of relapse activity.
• Current treatment paradigms for PMS are limited, representing a significant unmet clinical need.
• Emerging therapeutic strategies aim to address the underlying immunopathology of PMS.

Purpose of the Study:

• To review emerging therapies targeting CNS-compartmentalized inflammation in progressive multiple sclerosis (PMS).
• To highlight pivotal clinical trials evaluating novel immunomodulatory agents for PMS.
• To discuss the potential of these therapies to redefine PMS treatment by targeting key cellular pathways.

Main Methods:

• Review of six pivotal clinical trials for progressive multiple sclerosis (PMS).
• Focus on therapies including Bruton's tyrosine kinase (BTK) inhibitors, CD40-CD40L blockade, and CD19-directed chimeric antigen receptor (CAR)-T cells.
• Analysis of the mechanisms of action targeting microglia and B cell pathology.

Main Results:

• Several novel therapeutic classes are under investigation for PMS.
• These agents target distinct immune pathways implicated in neuroinflammation and neurodegeneration.
• Early data suggests potential for disease modification in progressive forms of MS.

Conclusions:

• Emerging therapies targeting CNS inflammation show promise for treating progressive multiple sclerosis (PMS).
• Modulating microglia and B cell activity represents a key strategy for future PMS treatments.
• These advancements may significantly improve outcomes for patients with unmet clinical needs in PMS.